Asset Details
Do you wish to reserve the book?
Translational Research in Spinal Cord Injury: A Survey of Opinion from the SCI Community
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Translational Research in Spinal Cord Injury: A Survey of Opinion from the SCI Community
Do you wish to request the book?
Translational Research in Spinal Cord Injury: A Survey of Opinion from the SCI Community
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Translational Research in Spinal Cord Injury: A Survey of Opinion from the SCI Community
2010
Overview
Much like our colleagues studying neuroprotection for acute stroke, we in the spinal cord injury (SCI) community have witnessed the preclinical emergence of numerous promising neuroprotective and neuro-regenerative treatments that have then disappointingly failed to demonstrate convincing efficacy in clinical trials. In contrast to the stroke field, the SCI community lacks guidelines to steer the preclinical development of therapies and maximize their chance of success prior to translation into expensive and laborious clinical trials. We conducted a survey of the SCI research community to garner perspectives on the question of what preclinical evidence was required before translating an experimental treatment into clinical trials. The opinions of the 324 respondents about what constitutes necessary preclinical evidence before moving to human SCI trials revealed strong support for the demonstration of efficacy in large-animal models, cervical injury models, and for independent replication of promising results. Marked differences exist between the sentiments of the respondents and the translational experience of our field. A framework for guiding the preclinical development of novel therapies prior to human translation would be helpful for ensuring clinical success. Greater dialogue on this issue is necessary to improve our chances of successfully bringing effective treatments to patients with this devastating injury.
Publisher
SAGE Publications,Mary Ann Liebert, Inc
Subject
/ Clinical Protocols - standards
/ Clinical Trials as Topic - standards
/ Drug Evaluation, Preclinical - methods
/ Drug Evaluation, Preclinical - trends
/ Evidence-Based Medicine - trends
/ Humans
/ Spinal Cord Injuries - physiopathology
/ Spinal Cord Injuries - therapy
